Depression remains one of the world’s most debilitating conditions, impacting millions worldwide with symptoms that can disrupt every facet of life — from work and relationships to basic daily functioning. For many, traditional antidepressants offer little relief, especially those facing treatment-resistant depression (TRD), where symptoms persist despite multiple therapies.
This growing unmet need is fueling a new frontier in mental health: Psychedelic medicine. Biotech firms are now exploring psychedelic compounds and therapeutics to rewire the brain and restore balance where conventional drugs have failed.
